A Phase I/II Dose Escalation Study of MK0457 in Patients With Leukemia
Interventional
Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
Safety and tolerability of MK0457 as 5 day infusion measured by duration, grade, and time of onset of toxicity. Plasma pK levels by dose level.
30 Months
Yes
Medical Monitor
Study Director
Merck
United States: Food and Drug Administration
2005_033
NCT00111683
June 2005
May 2008
Name | Location |
---|